SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cordova Ashley

(Last)

(First)

(Middle)

C/O NOVOCURE INC.,

20 VALLEY STREAM PARKWAY, SUITE 300

(Street)

MALVERN

19355

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/01/2020

3. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	7,348	D
Restricted Share Units	1,465⁽¹⁾	D
Restricted Share Units	1,006⁽²⁾	D
Restricted Share Units	5,314⁽³⁾	D
Restricted Share Units	5,405⁽⁴⁾	D
Restricted Share Units	5,904⁽⁵⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Options to Buy Ordinary Shares	⁽⁶⁾	04/22/2025	Ordinary Shares	13,840	$15.6	D
Options to Buy Ordinary Shares	⁽⁶⁾	02/24/2026	Ordinary Shares	8,936	$11.46	D
Options to Buy Ordinary Shares	⁽⁶⁾	07/27/2026	Ordinary Shares	2,480	$11.44	D
Options to Buy Ordinary Shares	⁽⁷⁾	02/21/2027	Ordinary Shares	9,752	$7.15	D
Options to Buy Ordinary Shares	⁽⁸⁾	03/21/2029	Ordinary Shares	14,595	$47.04	D
Options to Buy Ordinary Shares	07/26/2021	07/25/2027	Ordinary Shares	7,500	$19.25	D
Options to Buy Ordinary Shares	⁽⁹⁾	02/26/2028	Ordinary Shares	16,051	$21.5	D
Options to Buy Ordinary Shares	⁽¹⁰⁾	10/29/2028	Ordinary Shares	8,300	$32.02	D
Options to Buy Ordinary Shares	⁽¹¹⁾	03/02/2030	Ordinary Shares	10,422	$69.37	D
Options to Buy Ordinary Shares	⁽¹²⁾	08/31/2030	Ordinary Shares	11,336	$84.68	D

Explanation of Responses:

1. Represents restricted share units that are scheduled to vest on February 27, 2021, subject to the reporting person's continued employment through such date.

2. Represents restricted share units that are scheduled to vest in equal installments on each of October 30, 2020 and 2021, subject to the reporting person's continued employment through such dates.

3. Represents restricted share units that are scheduled to vest in equal installments on each of March 22, 2021 and 2022, subject to the reporting person's continued employment through such dates.

4. Represents restricted share units that are scheduled to vest in equal installments on each of March 3, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.

5. Represents restricted share units that are scheduled to vest in equal installments on each of September 1, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.

6. Currently exercisable.

7. Options to buy 9,752 ordinary shares, 2 shares of which are currently exercisable and the remainder vest on February 22, 2021.

8. Options to buy 14,595 ordinary shares, 3,649 shares of which are currently exercisable and the remaining 10,946 shares of which will vest and become exercisable in equal installments on each of March 22, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.

9. Options to buy 16,051 ordinary shares will vest and become exercisable in equal installments on each of February 27, 2021 and 2022, subject to the reporting person's continued employment through such dates.

10. Options to buy 8,300 ordinary shares will vest and become exercisable in equal installments on each of October 30, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates.

11. Options to buy 10,422 ordinary shares will vest and become exercisable in equal installments on each of March 3, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.

12. Options to buy 11,336 ordinary shares will vest and become exercisable in equal installments on each of September 1, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.

Remarks:

	By: /s/ Steven Robbins, Attorney in Fact for Ashley Cordova	09/10/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.